The Zhitong Finance App learned that recently, the reporter learned from JD Health (06618) that in the first half of 2026, JD Health launched a total of 65 new drugs, covering the fields of tumors, skin, chronic diseases, etc., leading the industry for many years in a row in the number of new drug launches.
JD Health is the pharmaceutical retail platform with the largest sales revenue for medical and health products in China. Throughout 2025, JD Health's total revenue reached 73.4 billion yuan, a year-on-year increase of 26.3%, and annual active users reached 218 million. The scale of pharmaceutical retail continued to lead the industry. It is this scale advantage that has enabled JD Health to build a service network with the longest life cycle and the widest coverage for service users, and to form a “medical examination and diagnosis” full-link closed-loop capability unique to the industry. Currently, the JD Health Service Network has covered millions of natural villages across the country.
Song Zhirui, vice president of JD Group and general manager of JD Healthcare Business Division, said in an interview with the media earlier that the platform plays the role of a “connector” and “accelerator” in the industrial chain. Take remibutinib tablets, which were first launched in March of this year, as an example. JD Health began marketing and joint construction with pharmaceutical companies in October of last year to assist demand forecasting and inventory planning through user data insight to ensure that new drugs reach patients everywhere as soon as possible.
What supports the efficient launch of 65 new drugs is the platform's broadest compliance network and the most complete service link. According to the data, third-tier cities and below account for more than 65% of JD health users. Nearly 100,000 township and village-level service sites have been set up across the country, and the coverage rate of same-day or next-day delivery in counties has reached 87.1%. From the “first kilometer” of the launch of a new drug to the “last mile” of long-term medication use by grassroots patients, JD Health has closed the entire link of “supply of all categories - efficient implementation - professional pharmaceutical services - intelligent AI management”. On the AI technology side, the AI doctor “Dawei” has completed hundreds of millions of interactions, with a praise rate of 98%. Nearly 70% of users come from third-tier cities and below; AI intelligent inventory scheduling accurately predicts drug demand in various regions, effectively reducing the risk of supply cuts.
The recently released “2026 Grassroots Drug Accessibility Research Report” confirms this status: JD Health's awareness among grassroots practitioners reached 67.3%, ranking first in the industry; 75.0% of respondents believe that online platforms should become an important part of the grassroots medication guarantee system. From the largest scale and the widest coverage to the longest life cycle of service users, JD Health is continuing to lead the way in launching new drugs and a complete closed loop of services, making the “first launch is inclusive” reality.